Format

Send to

Choose Destination
Urol Clin North Am. 2005 Nov;32(4):511-25, viii.

PDE-5 inhibitors: current status and future trends.

Author information

1
Department of Urology, College of Physicians and Surgeons, Columbia University, 161 Fort Washington Avenue, New York, NY 10032, USA.

Abstract

Phosphodiesterase-5 (PDE-5) inhibitors are a well-established, first-line therapy for erectile dysfunction (ED). Extensive clinical trials and clinical experience established the highly significant efficacy and the safety of this class of drugs in the treatment of ED.Furthermore, the efficacy of PDE-5 inhibitors has been established in men with ED with a broad range of etiologies and comorbidities. The future of PDE-5 inhibitors includes the expansion of indications such as the treatment of pulmonary hypertension and the potential of treatment of symptomatic BPH.

PMID:
16291042
DOI:
10.1016/j.ucl.2005.08.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center